Mark J. Van Duin

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Spatial profiling identifies a distinct and topographically-defined tumor microenvironment that emerges during multiple myeloma evolution.

Spatial profiling identifies a distinct and topographically-defined tumor microenvironment that emerges during multiple myeloma evolution.

Journal: Blood cancer discovery

Published: March 06, 2026

Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma.

Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma.

Journal: Blood cancer journal

Published: January 07, 2026

Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study.

Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study.

Journal: HemaSphere

Published: July 18, 2025

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Journal: Nature medicine

Published: June 27, 2025

European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma.

European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma.

Journal: HemaSphere

Published: June 16, 2025

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.

Journal: Blood

Published: June 03, 2025

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.

Journal: Blood

Published: May 29, 2025

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.

Journal: Blood

Published: May 29, 2025

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy.

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy.

Journal: Blood

Published: August 08, 2024

Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment?

Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment?

Journal: Frontiers in oncology

Published: June 26, 2023

An IL-1β-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma.

An IL-1β-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma.

Journal: Nature immunology

Published: March 24, 2023

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 31, 2022

Showing 1-12 of 41

Last Updated: 09/26/2026